A detailed history of Picton Mahoney Asset Management transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Picton Mahoney Asset Management holds 19 shares of HALO stock, worth $1,212. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19
Holding current value
$1,212
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Apr 02, 2025

BUY
$42.57 - $61.09 $808 - $1,160
19 New
19 $1,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.89B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Picton Mahoney Asset Management Portfolio

Follow Picton Mahoney Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Picton Mahoney Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Picton Mahoney Asset Management with notifications on news.